Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bamethan is a small molecule vasodilator and an adrenaline derivative developed by C. H. Boehringer Sohn. It acts primarily as a peripheral vasodilator, exerting its effect through stimulation of adrenergic beta-receptors, leading to relaxation of vascular smooth muscle and subsequent dilation of blood vessels. Bamethan has been used in the treatment of various peripheral vascular and circulatory disturbances, including peripheral artery disease, Raynaud's phenomenon, arteriosclerotic peripheral vascular disease, occlusive vascular disease of the legs, post-thrombotic syndrome, degenerative muscular disorders, and other conditions involving peripheral vascular insufficiency[2][3][4][5][8]. Its main clinical use is for improving blood flow in patients with compromised circulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bamethan.